We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apyx Medical (APYX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Apyx Medical (APYX - Free Report) closed at $6.31, marking a -0.63% move from the previous day. This change lagged the S&P 500's daily gain of 0.67%. At the same time, the Dow added 0.82%, and the tech-heavy Nasdaq gained 0.78%.
Prior to today's trading, shares of the medical device maker had lost 9.54% over the past month. This has lagged the Medical sector's gain of 0.38% and the S&P 500's gain of 1.25% in that time.
Wall Street will be looking for positivity from APYX as it approaches its next earnings report date. On that day, APYX is projected to report earnings of -$0.19 per share, which would represent a year-over-year decline of 533.33%. Meanwhile, our latest consensus estimate is calling for revenue of $5.83 million, down 41.23% from the prior-year quarter.
APYX's full-year Zacks Consensus Estimates are calling for earnings of -$0.71 per share and revenue of $25.51 million. These results would represent year-over-year changes of -144.83% and -17.68%, respectively.
Investors should also note any recent changes to analyst estimates for APYX. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 71.95% lower. APYX is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Apyx Medical (APYX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Apyx Medical (APYX - Free Report) closed at $6.31, marking a -0.63% move from the previous day. This change lagged the S&P 500's daily gain of 0.67%. At the same time, the Dow added 0.82%, and the tech-heavy Nasdaq gained 0.78%.
Prior to today's trading, shares of the medical device maker had lost 9.54% over the past month. This has lagged the Medical sector's gain of 0.38% and the S&P 500's gain of 1.25% in that time.
Wall Street will be looking for positivity from APYX as it approaches its next earnings report date. On that day, APYX is projected to report earnings of -$0.19 per share, which would represent a year-over-year decline of 533.33%. Meanwhile, our latest consensus estimate is calling for revenue of $5.83 million, down 41.23% from the prior-year quarter.
APYX's full-year Zacks Consensus Estimates are calling for earnings of -$0.71 per share and revenue of $25.51 million. These results would represent year-over-year changes of -144.83% and -17.68%, respectively.
Investors should also note any recent changes to analyst estimates for APYX. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 71.95% lower. APYX is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.